Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Ligand Pharmaceuticals was incorporated in 1987 and is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small-molecule drugs to address critical, unmet medical needs. Ligand markets four oncology and dermatology products in the US, namely Ontak, Targretin capsules, Targretin gel and Panretin gel, plus a fifth product, Avinza, has been launched to treat pain. In addition, Ligand's network of major pharmaceutical partners is developing products for men's and women's health, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases.